TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, have announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named TriGemX Bio, Inc. and is expected to trade on Nasdaq under the new ticker symbol TGEM. Latham & Watkins LLP represents TCGX in the transaction with a corporate team led by Houston partners Ryan Maierson and Ryan Lynch, with associates Taylor Allison, Cooper Shear, and Luisa Gomez Yokubaitis, with assistance from Zachary Mouton. Advice was also provided on tax matters by Houston partner Jared Grimley, with associates Dominick Constantino and Graham Core; on benefits matters by Los Angeles partner Michelle Carpenter, with associate Jordan Barnes; on healthcare regulatory matters by Washington, D.C. partner Nathan Beaton and counsel Nicole Liffrig Molife and Chad Jennings, with associate Margaret Rote; on funds matters by Chicago partner David Moore and New York partner Jennifer Tian;* on data cybersecurity matters by New York partner Jessica Cohen, with associates Laura Geraci and Nat Lewis; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Ryleigh Chen; on environmental matters by Los Angeles/Houston partner Joshua Marnitz, with associate Brandon Kerns; on anti-bribery and anti-money laundering matters by Washington, D.C. partner Daniel Dominguez, with associates Patricia Amselem Bensadon and Ai Ni Lim; on antitrust matters by Washington, D.C. partner Jason Cruise and Washington, D.C. counsel Ngoc Hulbig; and on economic sanctions and export controls matters by Washington, D.C. partner Eric Volkman, with associate Amulya Vadapalli. *Admitted to practice in Illinois only.